- citations in SCIndeks:
[1]
- citations in CrossRef:[1]
- citations in Google Scholar:[
 ]
- visits in previous 30 days:1
- full-text downloads in 30 days:0
|
|
|
2007, vol. 26, iss. 2, pp. 134-143
|
|
Breast cancer: Clinical implication
Karcinom dojke - Kliničke implikacije
Abstract
Breast cancer (BC) is a disease underlined by a complex aetiology, natural history and disease behaviour. Age is the greatest risk factor, which coupled with genetic predisposition, hormonal phenotype, reproductive profile and extrinsic factors, make BC the commonest malignancy in women (23%). The most frequent presenting symptom of BC is a hard, painless, irregular lump. Profile of BC, respective of it's growth and invasiveness capacity is diverse. Principle prognostic indicators are nodal status, tumour size histological grade and hormonal receptor status. Diagnosis is achieved by the combination of physical examination, FNAC or core biopsy and breast imaging (mammography/ ultrasound). Surgery remains the mainstay of BC treatment, with or without radiation therapy, chemotherapy, hormonal manipulation, and state-of-the-art targeted treatment. Even in this day-and-age, less than 55% of BC sufferers have an overall survival longer than 5 years. This raises an alarm to bring the long awaited and much researched patient-tailored treatment to the clinic at the fastest possible pace.
Sažetak
Karcinom dojke (KD) je bolest kompleksne etiologije, prezentacije karakteristika tumora i odgovora na terapiju. Starosna dob predstavlja najznačajniji faktor rizika, koji zajedno sa genetskom predispozicijom trajanjem i prirodom reproduktivnog perioda žene (rana menarha-kasna menopauza, nuliparitet, kasna prva trudnoća, ne-dojenje), i delovanjem spoljašnjih faktora rizika (nutricija, fizička aktivnost, pušenje), čini KD najčešćim malignitetom u žena. Vodeći simptom jeste bezbolna, čvrsta nepravilno ograničena masa u dojci. Dijagnoza se postavlja kombinacijom fizičkog pregleda, biopsije i neke od imidžing tehnika (mamografija ultrazvuk, MR). Najznačajniji prognostički parametri su veličina tumora nodalni status, histološki gradus, status hormonskih receptora. Hirurgija je i dalje osnova terapijskog pristupa, sa zračnom-, hemio-, hormono- ili ciljanom- terapijom, ili kombinacijom nekih od navedenih terapijskih modaliteta. I danas je petogodišnje preživljavanje od KD manje od 55%, što navodi na potrebu što hitnijeg uvođenja individualizovanog tretmana ove bolesti u kliničku praksu.
|
|
|
References
|
|
|
American Cancer Society (2002) Cancer fact sand figures, 2001-2002. Atlanta, Georgia
|
|
|
Burris, H. (2000) Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Seminars in Oncology, 27 (2 SUPPL. 3), str. 19-23
|
|
3 
|
Filipović, S. (1996) Osnovi kliničke onkologije. Niš: Prosveta
|
|
|
Frank, T.S., Manley, S.A., Olopade, O.I., Cummings, S., Garber, J.E., Bernhardt, B., Antman, K., i dr. (1998) Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology, 16 (7), str. 2417-2425
|
|
1  
|
Hartmann, L.C., Schaid, D.J., Woods, J.E., Crotty, T.P., Myers, J.L., Arnold, P.G., Petty, P.M., Sellers, T.A., Johnson, J.L., McDonnell, S.K., Frost, M.H., Jenkins, R.B. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med, 340(2): 77-84
|
|
|
Jacobs, T.W., Conolly, J.L., Schnitt, S.J. (2002) Non malignant leisions in breast core needle biopsie: To excise or not excise?. AM J Surg Pathol, 26, str. 185-197
|
|
|
Lynge, E. (2000) Recommendations on cancer screening in the European Union. European Journal of Cancer, 36(12), str. 1473-1478
|
|
1
|
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., i dr. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. Journal of Clinical Oncology, 23 (19), str. 4265-4274
|
|
|
Morris, A.D., Morris, R.D., Wilson, J.F., White, J., Steinberg, S., Okunieff, P., Arriagada, R., i dr. (1997) Breast-conserving therapy vs mastectomy in early-stage breast cancer: A meta-analysis of 10-year survival. Cancer Journal from Scientific American, 3 (1), str. 6-12
|
|
1
|
Nicolini, A., Carpi, A., Tarro, G. (2006) Biomolecular markers of breast cancer. Frontiers in Bioscience, 11(1): 1818
|
|
|
Perry, N., Breeders, M., Holand, R. (2006) European guidelines for quality assurance in breast cancer screening and diagnosis. Luxemburg: Office for Official Publications of the European Communities
|
|
|
Sewell, C.W. (2004) Pathology of high-risk breast lesions and ductal carcinoma in situ. Radiologic Clinics of North America, 42(5), str. 821-830
|
|
|
Silva, O.E., Zurrida, S. (2000) Breast Cancer: A Practical Guide. Elsevier
|
|
|
Stamatović, Lj. (2005) Adjuvantna hemioterapija raka dojke. in: Maligni tumori dojke, UOHS
|
|
|
Swenerton, K. (1997) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res, 39, str. 11-52
|
|
1
|
Šobić, V., Vučković-Dekić, Lj., Nešković-Konstantinović, Z. (2005) Novine u dijagnostici i terapiji karcinoma dojke. Akademija medicinskih nauka SLD-a
|
|
1
|
Taba'r, L., Duffy, S.W., Vitak, B., Chen, H.-H., Prevost, T.C. (1999) The natural history of breast carcinoma: What have we learned from screening?. Cancer, 86(3), str. 449-462
|
|
|
|
|